Evommune Shares Slide After Second Mid-Stage Miss for Oral Eczema Drug
The company will not advance the drug in eczema and shifts focus to EVO301.
/ 5 items
#EVMN↓
Evommune’s EVO756 Fails Phase 2b Trial in Chronic Spontaneous Urticaria, Development Discontinued
Evommune reported EVO756 failed to meet its primary endpoint in the Phase 2b CSU trial. The company is discontinuing development in urticaria but advancing the drug in atopic dermatitis with data expected in Q3 2026.
AbbVie Bolsters Immunology Pipeline with $10.9 Billion Apogee Acquisition
The acquisition would add a longer-acting alternative to Dupixent for inflammatory diseases.
EVO301 Meets Primary Endpoint in Phase 2a Study for Moderate-to-Severe Atopic Dermatitis
Evommune reports positive Phase 2a data for EVO301, showing 55% eczema reduction and a safe profile after 12 weeks of treatment.
Raymond James Starts Coverage on Evommune with Strong Buy Rating
Raymond James begins coverage of Evommune with a Strong Buy rating and a $40 price target, highlighting key Phase 2 clinical catalysts expected in 2026.